Navigation Links
Monogram Receives NASDAQ Notification
Date:10/3/2008

SOUTH SAN FRANCISCO, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that it received a staff deficiency letter from the Nasdaq Stock Market dated October 1, 2008 indicating that, for the previous 30 consecutive business days, the bid price of Monogram's common stock has closed below the minimum $1.00 per share requirement for continued listing under Nasdaq rules.

The letter stated that under Nasdaq rules, Monogram will be provided with 180 calendar days, or until March 30, 2009, to regain compliance with these rules. To regain compliance, the bid price of Monogram's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days, anytime before March 30, 2009. Additional detail regarding the relevant Nasdaq rules as they relate to Monogram's common stock will be included in the Company's filing on Form 8-K dated October 3, 2008.

"We continue to make progress in both our HIV and Oncology programs," said William Young, Monogram chief executive officer. "Our revenues have been at record levels in the first half of this year and we expect revenues to be greater than $60 million for the year, growth of over 40% over 2007. We expect further revenue growth in 2009 both from Trofile(TM), our patient selection assay for the CCR5 antagonist class of HIV drugs, and from HERmark(TM), our recently launched breast cancer assay."

"Our stockholders have previously authorized a reverse split of our common stock, to be implemented by the board of directors at any time prior to this year's annual stockholders meeting," added Young. "We continue to evaluate the appropriate circumstances for implementation of one of the authorized reverse split ratios." <
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
4. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
5. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
6. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
7. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
8. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
9. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
10. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
11. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... YORK, Jan. 15 - The Michael J. Fox,Foundation ... total funding for seven research studies aiming to ... drug makers, to,therapeutically target two genes -- LRRK2 ... only partially understood, role in Parkinson,s disease., ...
... Kan., Jan. 15 The Kansas Bioscience,Authority ... bring together,researchers nationwide to create products that ... diseases to disrupt the national economy or,to ... new Collaborative Biosecurity Research Initiative,(CBRI) are to ...
... Group plc (AIM:,PRG), the international pharmaceutical services ... Senior Director, Clinical Trial Management,specializing in oncology-related ... a leading role in the operations, strategic ... portfolio of oncology,business., Over the past ...
Cached Biology Technology:The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinson's Disease 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 3Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management 2
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... FL. Research to be presented at the upcoming ... Ingestive Behavior (SSIB), the foremost society for research into ... people can become dependent on highly palatable foods and ... the behaviors we observe in drug addicts and those ...
... can make a significant contribution to carbon storage and, ecologists ... and gardeners planted and maintained more trees. The study, published ... Applied Ecology , is the first to quantify how much ... Europe. Using satellite data and information gathered by visiting ...
... Toronto, ON - When it comes to how they ... from humans. Recent studies showed that even genetically ... a disease. This is because each twin has distinct personal ... the same is likely true for forest trees as well, ...
Cached Biology News:Evidence for 'food addiction' in humans 2Plants in cities are an underestimated carbon store 2New research shows forest trees remember their roots 2
... bromide), 50mg/vial. MTT is a pale yellow ... to yield a dark blue formazan product. ... freshly dead cells do not cleave significant ... component of Chemicons MTT assay kit, Catalog ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
Biology Products: